Polyrizon Ltd. PLRZ
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS4.90
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $2.1M | $534.0K | $332.0K | $347.0K | — |
| SG&A | $4.1M | $768.0K | $303.0K | $548.0K | — |
| Operating income | -$6.2M | -$1.3M | -$635.0K | -$895.0K | — |
| Net income | -$3.3M | -$1.5M | -$600.0K | -$779.0K | — |
| EPS, basic | 4.90 | 805.20 | 494.40 | 0.60 | — |
| EPS, diluted | 4.90 | 805.20 | 494.40 | 0.60 | — |
| Shares, diluted (wtd. avg.) | 680,380 | 1,994 | 1,354 | 1.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $2.6M | $4.0K | $36.0K | $523.0K |
| Short-term investments | — | — | $37.0K | — | — |
| Total current assets | $12.9M | $2.7M | $54.0K | — | — |
| Property, plant and equipment | $12.0K | $10.0K | $12.0K | — | — |
| Other intangibles | $2.5M | $2.9M | — | — | — |
| Total assets | $21.4M | $5.5M | $559.0K | — | — |
| Accounts payable | $294.0K | $216.0K | $158.0K | — | — |
| Total current liabilities | $443.0K | $261.0K | $502.0K | — | — |
| Retained earnings | -$8.4M | -$5.1M | -$3.5M | — | — |
| Total equity | $21.0M | $5.3M | -$191.0K | -$900.0K | -$251.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | -$1.1M | -$537.0K | -$1.1M | — |
| Depreciation and amortisation | $342.0K | $118.0K | $4.0K | $5.0K | — |
| Stock-based compensation | $1.3M | $51.0K | $100.0K | $130.0K | — |
| Capital expenditure | $7.0K | — | — | $3.0K | — |
| Investing cash flow | -$16.5M | $29.0K | — | -$3.0K | — |
| Financing cash flow | $19.8M | $3.7M | $505.0K | $648.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035204.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$779.0K | -$600.0K | -$1.5M | -$3.3M |
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |